Research peptide
BPC-157
Tissue repair, inflammation reduction, and gut lining integrity.
Emerging evidence
Peptide Therapy · Colorado Springs
Targeted signaling forrecovery, hormones, healthspan.
Peptides are among the most discussed and most misunderstood tools in functional medicine. This page covers what peptide therapy actually is, what the evidence supports, what it does not, and how Genesis uses peptides within structured protocols.
Physician-led · 503A/503B pharmacy · Evidence-graded
What is a peptide?
Signaling, not saturation.
A peptide is a short chain of amino acids: the same building blocks as proteins, but smaller. Most peptides in clinical use contain between 2 and 50 amino acids. Because of their size, they interact with specific receptor sites with precision that larger molecules often lack.
Where a supplement might provide a nutrient your body uses diffusely, a peptide sends a precise signal to a specific receptor or pathway. This is one reason why the side-effect profile of many peptides is notably different from systemic pharmaceuticals.
Categories we offer
Six clinical categories.
Metabolic & weight loss
GLP-1 therapy, AOD-9604. Anchored in the Weight Loss & Wellness Stack.
Learn more
Evidence at a glance
What the research actually shows.
Honest grading of the peptides in our stacks. Strong, moderate, emerging, weak, or very weak.
GLP-1 (semaglutide, tirzepatide)
Strong evidenceFDA-approved · Phase III RCTs (STEP, SURMOUNT).
Tesamorelin
Strong evidenceFDA-approved (Egrifta) · Phase III RCTs.
PT-141
Moderate evidenceFDA-approved (Vyleesi) for HSDD in women.
GHK-Cu (topical)
Moderate evidenceClinical studies support collagen synthesis.
BPC-157
Emerging evidencePreclinical + 2 small Croatian human trials.
TB-500
Emerging evidencePreclinical only for musculoskeletal.
MOTS-C
Weak evidenceMitochondrial peptide; preclinical.
AOD-9604
Weak evidencePhase IIb obesity endpoint not met; mechanistic preclinical only.
Epitalon
Very weak evidenceRussian observational + in vitro.
Peptides we offer
Browse the catalog.
- Research peptide
TB-500
Connective tissue and recovery support.
Emerging evidence - FDA-approved
Tesamorelin
Visceral fat reduction via growth hormone axis support.
Strong evidence - Research peptide
MOTS-C
Mitochondrial efficiency, metabolic flexibility, and endurance.
Weak evidence - 503A compounded
GHK-Cu Peptide
Collagen and elastin synthesis. Skin rejuvenation and hair health.
Emerging evidence - FDA-approved
GLP-1 Therapy
Appetite regulation and clinically guided metabolic weight loss.
Strong evidence - 503A compounded
AOD-9604
Targeted stubborn fat mobilization with no appetite or blood sugar effect.
Weak evidence - FDA-approved
PT-141
CNS-level libido and arousal support for men and women.
Moderate evidence - Research peptide
Epitalon
Circadian rhythm regulation, telomere support, cellular longevity.
Very weak evidence
Status & disclosures
- FDA status varies
- Some peptides on this page are FDA-approved for specific indications. Others are 503A-compounded or research peptides. Each therapy page discloses status clearly.
- Compounding
- 503A pharmacies prepare patient-specific formulations under USP <797> sterile standards. Genesis works only with licensed compounding partners.
- Off-label use
- Several peptides on this page are used off-label. Informed consent is reviewed at the GFE.
Frequently asked
Common questions about peptide therapy.
Peptide therapy is the clinical use of compounded or synthetic peptide compounds to achieve specific physiological effects: stimulating tissue repair, modulating hormones, supporting immune function, or enhancing cognitive signaling.
Safety depends on the peptide, the dose, and the patient. FDA-approved peptides (like Vyleesi or Egrifta) have established safety profiles. 503A-compounded and research peptides have variable evidence. Genesis discloses the evidence and FDA status of every peptide on its therapy page.
503A-compounded peptides prepared under valid prescriptions by licensed pharmacies are legal. Some research peptides are in regulatory review. Genesis works only with licensed compounding pharmacies.
Most therapeutic peptides are delivered subcutaneously (SQ injection), intramuscularly (IM), intranasally, or intravenously. Oral bioavailability is poor for most peptides.
Sources
Citations & references
- [1]Falutz J et al. Effects of tesamorelin on visceral fat. JAMA. 2014. Source
- [2]Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008.
- [3]Sikiric P et al. BPC 157 stable gastric pentadecapeptide. Curr Pharm Des. 2018.
Next step
Talk to a Genesis provider about peptide therapy.
Schedule a consultation. Physician-led, evidence-graded.
Or keep reading: Or browse the Restore & Recover stack